

Editorial

Integrative proteomics and metabolomics: Bridging molecular complexity and clinical translation

Tikam Chand Dakal

Genome and Computational Biology Lab, Department of Biotechnology, Mohanlal Sukhadia University, Udaipur, Rajasthan, India

***Correspondence to:** Tikam Chand Dakal; tikam26070@gmail.com

Citation: Dakal., T. N. (2025) Integrative proteomics and metabolomics: Bridging molecular complexity and clinical translation. *Sci Academique* 6(2): 106-111

Received: 24 November, 2025; **Accepted:** 05 December, 2025; **Published:** 11 December, 2025

Abstract

The emergence of omics technologies has revolutionized biomedical science, enabling unprecedented insights into the molecular foundations of health and disease. Among these, proteomics and metabolomics have proven particularly powerful for decoding the biochemical and physiological states of living systems (Figure 1). Together, they capture both the functional and dynamic layers of biology, proteins as effectors and metabolites as immediate products of cellular activity, providing a multidimensional view of molecular processes in real time [1,2].




Figure 1: Understanding Cellular, Molecular and Physiological Aspects of Biological Systems Using Proteomics and Bioinformatics

From Discrete Disciplines to Integrated Systems

Initially, each omics field evolved independently, generating vast yet fragmented datasets. Recent advances in multi-omics integration and systems biology now allow researchers to merge proteomic and metabolomic data, uncovering relationships between enzyme function, metabolic flux, and disease phenotypes [3]. This integration is transforming our understanding of pathophysiology, from cancer and cardiovascular disorders to neurodegeneration, by linking molecular mechanisms to clinical outcomes [4]

Post-Translational Modifications: Fine-Tuning Protein Function

Proteomics has illuminated the diversity of post-translational modifications (PTMs) that fine-tune protein function. Modifications such as phosphorylation, acetylation, ubiquitination, and glycosylation regulate enzyme activity, localization, and signalling pathways [5]. PTM mapping through high-resolution mass spectrometry (MS) and enrichment techniques provides insights into dynamic signalling events underlying inflammation, metabolism, and cancer progression [6]. These protein-level changes complement metabolomic data, revealing how alterations in metabolic intermediates correspond to shifts in cellular signalling.

Technological Advances in Proteomics and Metabolomics

The field's growth has been driven by advances in analytical platforms such as liquid chromatography–tandem mass spectrometry (LC–MS/MS) and nuclear magnetic resonance (NMR) spectroscopy [7]. Modern MS technologies now allow label-free quantification, single-cell proteomics, and deep coverage of post-translational landscapes [8]. Metabolomics has evolved concurrently, with targeted and untargeted approaches revealing biomarkers across a spectrum of diseases, from metabolic syndromes to neurodegenerative and hepatic disorders [9]

Liquid biopsy metabolomics, using plasma, saliva, urine, or cerebrospinal fluid, has emerged as a minimally invasive diagnostic frontier, offering early disease detection and therapy monitoring [10]. Lipidomics, a specialized branch of metabolomics, now provides detailed maps of lipid species central to cell signalling, membrane integrity, and metabolic regulation [11].

Biomedical Applications and Disease Insights

Proteomic and metabolomic profiling have identified novel biomarkers and therapeutic targets across a wide range of pathologies. In cancer research, integrated omics approaches are revealing tumor-specific metabolic signatures and protein interaction networks that drive malignancy [12]. Metabolomic profiling has also shed light on pregnancy-related conditions, including preeclampsia and intrauterine growth restriction, through alterations in lipid and energy metabolism [13]. In infectious disease research, proteomics has elucidated host–pathogen interactions and immune responses, while metabolomics has identified metabolic disruptions that underlie disease progression [14]. Similarly, neuroproteomics and neurometabolomics are revealing pathways associated with neurodegenerative conditions such as Alzheimer's and Parkinson's disease [15].

Computational and Methodological Developments

The integration of AI and machine learning (ML) is reshaping data interpretation in proteomics and metabolomics. Algorithms capable of recognizing molecular patterns are now applied for biomarker discovery, pathway reconstruction, and predictive modelling [16]. Additionally, innovations in sample preparation, ion mobility spectrometry, and spatial metabolomics have enhanced molecular coverage and spatial resolution, bridging the gap between analytical chemistry and clinical pathology [17]. Emerging approaches such as proteogenomic and interactomics further expand the scope of proteomic research, linking genomic variation to protein expression and interaction networks [18]. These strategies enhance precision medicine by connecting molecular alterations with therapeutic responsiveness.

Challenges and the Path Forward

Despite rapid progress, challenges persist. Issues of data reproducibility, standardization, and cross-platform comparability continue to hinder large-scale integration [19]. Initiatives promoting FAIR (Findable, Accessible, Interoperable, Reusable) data principles and global

repositories such as PRIDE and MetaboLights are helping ensure transparency and accessibility [20]. Looking ahead, the synergy between multi-omics technologies, AI-driven analytics, and clinical translation promises to redefine biomedicine. The convergence of proteomics and metabolomics not only deepens our molecular understanding but also opens pathways toward precision diagnostics, targeted therapeutics, and systems-level disease modelling. As research continues to bridge molecular complexity with clinical application, these integrative approaches will form the cornerstone of 21st-century personalized medicine.

References

1. Aebersold, R., Mann, M. (2016). Mass-spectrometric exploration of proteome structure and function. *Nature*, 537(7620), 347–355. <https://doi.org/10.1038/nature19949>
2. Patti, G. J., Yanes, O., Siuzdak, G. (2012). Innovation: Metabolomics: The apogee of the omics trilogy. *Nature Reviews Molecular Cell Biology*, 13(4), 263–269. <https://doi.org/10.1038/nrm3314>
3. Misra, B. B., Langefeld, C., Olivier, M., Cox, L. A. (2019). Integrated omics: Tools, advances and future approaches. *Journal of Molecular Endocrinology*, 62(1), R21–R45. <https://doi.org/10.1530/JME-18-0055>
4. Johnson, C. H., Ivanisevic, J., Siuzdak, G. (2016). Metabolomics: Beyond biomarkers and towards mechanisms. *Nature Reviews Molecular Cell Biology*, 17(7), 451–459. <https://doi.org/10.1038/nrm.2016.25>
5. Olsen, J. V., Mann, M. (2013) Status of large-scale analysis of post-translational modifications by mass spectrometry. *Molecular & Cellular Proteomics*, 12(12), 3444–3452. <https://doi.org/10.1074/mcp.O113.034181>
6. Khoury, G. A., Baliban, R. C., Floudas, C. A. (2011). Proteome-wide post-translational modification statistics: Frequency analysis and curation of the Swiss-Prot database. *Scientific Reports*, 1, 90. <https://doi.org/10.1038/srep00090>
7. Pang, Z., Chong, J., Li, S., & Xia, J. (2021). MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. *Nucleic Acids Research*, 49(W1), W388–W396. <https://doi.org/10.1093/nar/gkab382>
8. Budnik, B., Levy, E., Harmange, G., & Slavov, N. (2018). SCoPE-MS: Mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation. *Genome Biology*, 19(1), 161–176. <https://doi.org/10.1186/s13059-018-1547-5>
9. Nicholson, J. K., Holmes, E., & Wilson, I. D. (2012). Gut microorganisms, mammalian metabolism and personalized health care. *Nature Reviews Microbiology*, 10(4), 259–266. <https://doi.org/10.1038/nrmicro1152>
10. Gowda, G. A. N., Zhang, S., Gu, H., Asiago, V., Shanaiah, N., & Raftery, D. (2008). Metabolomics-based methods for early disease diagnostics. *Expert Review of Molecular Diagnostics*, 8(5), 617–633. <https://doi.org/10.1586/14737159.8.5.617>
11. Shevchenko, A., & Simons, K. (2010). Lipidomics: Coming of age. *Nature Reviews Molecular Cell Biology*, 11(8), 593–598. <https://doi.org/10.1038/nrm2934>
12. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, 144(5), 646–674. [Google Scholar](https://doi.org/10.1016/j.cell.2011.02.013)
13. Griffin, J. L., Atherton, H. J., Shockcor, J. P., & Atzori, L. (2015). Metabolomics as a tool for cardiac research. *Nature Reviews Cardiology*, 12(11), 651–667. <https://doi.org/10.1038/nrcardio.2011.138>

14. Chong, J., Wishart, D. S., & Xia, J. (2018). Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. *Current Protocols in Bioinformatics*, 68(1), e86–e99. <https://doi.org/10.1002/cpbi.86>
15. Wilkins, J. M., & Trushina, E. (2018). Application of metabolomics in Alzheimer’s disease. *Frontiers in Neurology*, 8, 719. <https://doi.org/10.3389/fneur.2017.00719>
16. Ernst, M., Simo, C., & Broadhurst, D. (2020). Machine learning approaches for metabolomics and proteomics data analysis. *Trends in Analytical Chemistry*, 129, 115934.
17. Rappez, L., Stadler, M., Triana, S., et al. (2021). Spatial metabolomics of tissues using MALDI-MS imaging combined with optical microscopy. *Nature Protocols*, 16(2), 1159–1182.
18. Mertins, P., Mani, D. R., Ruggles, K. V., et al. (2016). Proteogenomics connects somatic mutations to signalling in breast cancer. *Nature*, 534(7605), 55–62. <https://doi.org/10.1038/nature18003>
19. Vizcaíno, J. A., Deutsch, E. W., Wang, R., et al. (2014). ProteomeXchange provides globally coordinated proteomics data submission and dissemination. *Nature Biotechnology*, 32(3), 223–226. <https://doi.org/10.1038/nbt.2839>
20. Perez-Riverol, Y., Csordas, A., Bai, J., et al. (2019). The PRIDE database and related tools and resources in 2019: Improving support for quantification data. *Nucleic Acids Research*, 47(D1), D442–D450. <https://doi.org/10.1093/nar/gky1106>